Table 4.
Correlation of IHC‐QDs or FISH with Response and TTP during trastuzumab therapy in six patients
| No. | Age | Stage | ER/PgR | Metastatic site | FISH | IHC‐DAB | IHC‐QDs | Responsea | TTP (month) |
|---|---|---|---|---|---|---|---|---|---|
| Case 32 | 60 | IIB | −/− | Liver | 4.25 | 3 | 8.17 | SD | 12 |
| Case 33 | 31 | I | −/− | Lung | 4.53 | 3 | 8.26 | PD | 3 |
| Case 34 | 74 | IIIC | −/− | Liver | 6.90 | 2 | 9.69 | PD | 3 |
| Case 35 | 32 | IIB | +/+ | Lung | 2.55 | 3 | 10.26 | SD | 27 |
| Case 36 | 73 | IIIA | −/− | Liver | 4.13 | 3 | 11.32 | PR | 50 |
| Case 37 | 36 | IIB | −/− | Bone | 7.90 | 3 | 12.17 | SD | 24 |
a
Response criteria is based on RECIST guideline.
PR, partial response; SD, stable disease; PD, progression disease 24; TTP, Time to progression.